Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update - Document - Gale OneFile: Health and Medicine
![Restoring the upward trend in blood pressure control rates in the United States: a focus on fixed-dose combinations | Journal of Human Hypertension Restoring the upward trend in blood pressure control rates in the United States: a focus on fixed-dose combinations | Journal of Human Hypertension](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41371-020-0340-6/MediaObjects/41371_2020_340_Fig1_HTML.png)
Restoring the upward trend in blood pressure control rates in the United States: a focus on fixed-dose combinations | Journal of Human Hypertension
![Equivalent dosing of irbesartan, valsartan, and losartan identified through formulary switch at a Veterans Affairs medical center Equivalent dosing of irbesartan, valsartan, and losartan identified through formulary switch at a Veterans Affairs medical center](https://cdn.sanity.io/images/0vv8moc6/formularywatch/e37714a0e388feff569f7e91e3c258dd9a03a8e8-200x128.jpg)
Equivalent dosing of irbesartan, valsartan, and losartan identified through formulary switch at a Veterans Affairs medical center
Angiotensin Converting-Enzyme Inhibitors, Angiotensin Receptor Blockers, and Calcium Channel Blockers Are Associated with Prolonged Vascular Access Patency in Uremic Patients Undergoing Hemodialysis
![Equivalent dosing of irbesartan, valsartan, and losartan identified through formulary switch at a Veterans Affairs medical center Equivalent dosing of irbesartan, valsartan, and losartan identified through formulary switch at a Veterans Affairs medical center](https://cdn.sanity.io/images/0vv8moc6/formularywatch/2116722128441a75af7a059b15b119a151795570-187x150.jpg)
Equivalent dosing of irbesartan, valsartan, and losartan identified through formulary switch at a Veterans Affairs medical center
![ACE Inhibition versus Angiotensin Receptor Blockade: Which Is Better for Renal and Cardiovascular Protection? | American Society of Nephrology ACE Inhibition versus Angiotensin Receptor Blockade: Which Is Better for Renal and Cardiovascular Protection? | American Society of Nephrology](https://jasn.asnjournals.org/content/jnephrol/15/1_suppl/S64/F1.large.jpg?download=true)
ACE Inhibition versus Angiotensin Receptor Blockade: Which Is Better for Renal and Cardiovascular Protection? | American Society of Nephrology
![Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan | SpringerLink Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-018-0859-x/MediaObjects/12325_2018_859_Fig1_HTML.png)
Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan | SpringerLink
![PDF) Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration ... PDF) Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration ...](https://www.researchgate.net/publication/338762140/figure/fig1/AS:850321597280256@1579743875053/Study-design-Abbreviations-BP-blood-pressure-V-Visit-W-week_Q320.jpg)
PDF) Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration ...
![PDF] Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT): Rationale and Study Design | Semantic Scholar PDF] Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT): Rationale and Study Design | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bcf5a751b2ba4467266d3ebdddc74f2fd8ee0b51/5-Table3-1.png)